Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Skye Bioscience Inc. | Nimacimab - (CBeyond) | Obesity | Phase 2a | Data Released | Intravenous | Endocrinology |
| Skye Bioscience Inc. | SBI-100 | Primary open-angle glaucoma (POAG) or Ocular hypertension (OHT) | Phase 2a | Trial Discontinued | Inhalation | Opthalmic |
| Sol-Gel Technologies Ltd. | SGT-610 (patidegib) | Gorlin syndrome | Phase 3 | Enrollment Initiation | Topical | Genetic Disorder |
| Sol-Gel Technologies Ltd. | SGT-610 (patidegib) | Gorlin syndrome | Phase 3 | Enrollment Initiation | Topical | Genetic Disorder |
| Sol-Gel Technologies Ltd. | SGT-510 - (Roflumilast combination with Tapinarof) | Psoriasis & Other Dermatological Indications | Phase 2 | Trial Discontinued | Topical | Immunology |
| Soleno Therapeutics Inc. | Diazoxide Choline Controlled-Release (DCCR) - (DESTINY PWS) | Prader-Willi syndrome (PWS) | Phase 3 | Data Released | Oral | Genetic Disorder |
| Soligenix Inc. | HyBryte vs Valchlor | Cutaneous T-cell lymphoma (CTCL) | Phase 3 | Data Released | HyBryte topical Valchlor topical | Oncology |
| Soligenix Inc. | RW-HPN-MF-01 | Mycosis Fungoides | Phase 3 | Trial Completed | Oral | Oncology |
